For research use only · Not for human consumption
This material is reference information for laboratory study of research peptides. It is not medical advice and it is not instructions for human use, self-administration, or therapeutic application. Capital Peptides supplies research chemicals for in-vitro and animal-model study only. Discuss any health-related questions with a licensed medical practitioner.
1. Taper vs. cold stop
For the majority of research peptides, a cold stop (stopping at full dose immediately) is appropriate and does not cause withdrawal or rebound effects. Peptides are not anabolic steroids — most don't suppress the HPTA, so there's no hormonal crash to manage.
| Peptide type | Cold stop | Taper |
|---|---|---|
| BPC-157, TB-500 (healing) | ✓ Cold stop fine | Not required |
| GH secretagogues (CJC, Ipa, GHRP) | ✓ Cold stop fine | Optional if you prefer a gradual transition |
| GLP-1 agonists (high dose, extended use) | Generally fine; some prefer step-down | Useful if managing rebound appetite |
| Cognitive peptides (Semax, Selank) | ✓ Cold stop fine | Not required |
| Bioregulators (Epithalon, etc.) | ✓ Cold stop fine | Not required |
2. What to monitor post-cycle
The 4–6 weeks after stopping a cycle is a useful observation window:
- GH-axis protocols: Monitor IGF-1 levels at 4–6 weeks post-cycle. They should return to your pre-cycle baseline. If still elevated, it suggests you were using a longer-acting compound (like CJC-1295 with DAC) that has extended clearance. Also check fasting glucose — GH-stimulated insulin resistance should normalise.
- Weight and body composition: Expect 1–2 kg of water weight loss within 1–2 weeks of stopping GH secretagogues. This is the retained fluid resolving — not fat gain or muscle loss.
- Healing protocols: Assess the target injury/condition at 2–4 weeks post-cycle. Healing continues after stopping — the peptide initiates repair pathways that continue independently.
- Cognitive protocols: Note when baseline cognition (without the peptide) returns, and whether there is a period of rebound fatigue or lower clarity. This informs your off-period duration.
3. Retaining results
Results from different peptide classes have different persistence:
| Goal / class | Post-cycle result retention |
|---|---|
| Structural healing (BPC, TB-500) | Permanent — repaired tissue remains repaired. Results don't reverse. |
| Body composition (GH-axis) | High if you maintain training and nutrition. Muscle doesn't disappear; fat stays off if diet is maintained. |
| Fat loss (GLP-1 agonists) | Moderate — appetite returns after stopping; weight regain is common without lifestyle maintenance. |
| Cognitive (Semax, Selank) | Not persistent — requires ongoing dosing for maintained effect. Washout is complete. |
| Sleep quality improvement | Some baseline improvement often persists; the acute GH-pulse enhancement fades within 1–2 weeks. |
4. Specific guidance by compound class
CJC-1295 with DAC
Has a long half-life (~7 days). 'Coming off' is a 2–3 week process as the compound clears. Plan your off-period starting from the last injection date, not the last day of significant effect.
CJC-1295 No-DAC / Modified GRF(1-29)
Short half-life — clears within hours. Cold stop is straightforward; effects cease within 24–48 hours of last injection.
Semaglutide / Tirzepatide
Half-life of ~7 days (semaglutide) or ~5 days (tirzepatide). Plan the cycle end to coincide with your goals. Appetite will return within 1–2 weeks of the last injection as levels decline.
BPC-157 / TB-500
Short half-life — rapid clearance. Results from healing protocols persist after stopping. Simply stop dosing at the end of your protocol.